Encyclopedia of Medical Immunology

2014 Edition
| Editors: Ian R. Mackay, Noel R. Rose, Dennis K. Ledford, Richard F. Lockey

Topical Preparations: Calcineurin Inhibitors

  • Kamila Dell
  • Gwendolyn Wantuch
  • Nathan Seligson
Reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9194-1_247


Anti-inflammatory agent; Immunosuppressant agent; Topical skin product


Topical calcineurin inhibitors (TCIs) are immunomodulatory preparations designed to suppress local immune-related reactions. Due to this mechanism of action, TCIs are approved for use in atopic dermatitis (AD) as second-line therapy (Astellas Pharma US, Inc 2012; Novartis Pharma Produktions GmbH 2011; Schneider et al. 2013). TCIs are often utilized in patients who have altered sensitivity to or poor therapeutic response with corticosteroid related treatment. In comparison to corticosteroids, TCIs can be used on most skin surface areas of the body as application does not result in skin atrophy and thinning (Schneider et al. 2013; Frankel and Qureshi 2012). Studies support the safety and efficacy of TCIs for treatment of AD; however, TCIs have not been studied in patients receiving treatment for greater than 1 year. Therefore, caution is warranted for long-term treatment of AD with TCIs.


This is a preview of subscription content, log in to check access.


  1. Abramovits W, Fleischer Jr AB, Jaracz E, et al. Adult patients with moderate atopic dermatitis: tacrolimus ointment verus pimecrolimus cream. J Drugs Dermatol. 2008;7(12):1153–8.PubMedGoogle Scholar
  2. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ. 2005;330(7490):516–24.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144–56.PubMedCrossRefGoogle Scholar
  4. Fleischer Jr AB, Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat. 2007;18(3):151–7.PubMedCrossRefGoogle Scholar
  5. Frankel CH, Qureshi AA. Comparative effectiveness of topical calcinurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol. 2012;13(2):113–23.PubMedCrossRefGoogle Scholar
  6. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271–7.PubMedCrossRefGoogle Scholar
  7. Pimecrolimus [package insert]. Wehr: Novartis Pharma Productions GmbH; 2011.Google Scholar
  8. Schneider L, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131:295–9.PubMedCrossRefGoogle Scholar
  9. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin Immunol. 2013;9:24.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Tacrolimus [package insert]. Northbrook: Astellas Pharma US, Inc; 2012.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Kamila Dell
    • 1
  • Gwendolyn Wantuch
    • 1
  • Nathan Seligson
    • 2
  1. 1.Department of Pharmacotherapeutics and Clinical ResearchUniversity of South Florida, College of PharmacyTampaUSA
  2. 2.The University of South Florida College of PharmacyTampaUSA